Intellia Therapeutics, Inc.: Intellia Therapeutics Announces

Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND

Related Keywords

New York , United States , Cambridge , Cambridgeshire , United Kingdom , America , Ian Karp , Rebecca Spalding , John Leonard , Alina Li , Bill Chase , Las Vegas , Exchange Commission , Company Environmental , Vivo Program Updates , Nasdaq , Regeneron Pharmaceuticals Inc , Intellia Therapeutics Inc , Therapeutics Inc , Health Care Conference , Twitter , Drug Administration , Regulatory Agency , Regulatory Agency Innovation Passport , Corporate Communications , Company At The Market , Drug Administration Regenerative Medicine Advanced Therapy , Intellia President , Chief Executive Officer John Leonard , Recent Operational , Regeneron Pharmaceuticals , New Drug , Regenerative Medicine Advanced Therapy , Innovation Passport , Access Pathway , Associated Lung Disease , Associated Liver Disease , Autoimmune Diseases , Pipeline Expansion , Directors Update , Caroline Dorsa , Responsibility Report , America Securities , Care Conference , Markets Global Healthcare Conference , Gene Editing , Therapy Summit , Genetic Medicines Day , Rewrite Therapeutics , Discuss First Quarter , Intellia Therapeutics , Private Securities Litigation Reform Act , Months Ended March , Vice President , Investor Relations , Intellia , Herapeutics , Nnounces , First , Quarter , 023 , Financial , Results , Highlights , Ecent , Company , Progress ,